Generic Name:
zanubrutinib
Project Status:
Complete
Therapeutic Area:
Waldenström’s macroglobulinemia
Manufacturer:
BeiGene, Ltd.
Brand Name:
Brukinsa
Project Line:
Reimbursement Review
Project Number:
PC0248-000
Tumour Type:
Lymphoma
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with Waldenström’s macroglobulinemia (WM)
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of patients with Waldenström’s macroglobulinemia (WM)
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.